Key facts
- This page summarizes Christopher Heery's Form 4 filing for Arcellx, Inc. (ACLX).
- 4 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 10 Jan 2025, 21:38.
Christopher Heery - 07 Jan 2025 Form 4 Insider Report for Arcellx, Inc. (ACLX)
- Reporting relationship
- CHIEF MEDICAL OFFICER
- Issuer ticker
- ACLX
- Reported as of
- 07 Jan 2025
- Net transaction value
- -$581,316
- SEC form
- 4
- Accepted by SEC
- 10 Jan 2025, 21:38:15 UTC
- Prior SEC filing
- 10 Jan 2025
- Next SEC filing
- 11 Feb 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Michelle Gilson, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Christopher Heery filed Form 4 for Arcellx, Inc. (ACLX) on 10 Jan 2025.
Change
- Previous filing in this sequence was filed on 10 Jan 2025.
- Current net transaction value: -$581,316.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ACLX
transaction
Common Stock
Options Exercise
- Transaction value
- $0
- Shares
- +16,519
- Change %
- +74%
- Price
- $0.000000
- Shares after
- 38,818
- Date
- 03 Jan 2025
- Ownership
- Direct
- Footnotes
- F1
ACLX
transaction
Common Stock
Sale
- Transaction value
- $319,485
- Shares
- -4,230
- Change %
- -13%
- Price
- $75.53
- Shares after
- 28,638
- Date
- 07 Jan 2025
- Ownership
- Direct
- Footnotes
- F2, F3
ACLX
transaction
Common Stock
Sale
- Transaction value
- $261,831
- Shares
- -3,553
- Change %
- -12%
- Price
- $73.69
- Shares after
- 25,085
- Date
- 08 Jan 2025
- Ownership
- Direct
- Footnotes
- F2, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ACLX
transaction
Derivative
Restricted Stock Unit
Options Exercise
- Transaction value
- $0
- Shares
- -16,519
- Change %
- -50%
- Price
- $0.000000
- Shares after
- 16,520
- Date
- 03 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 16,519
- Exercise price
- Footnotes
- F1, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Vesting of these RSUs previously reported in the Form 4 filed January 6, 2025.
Footnote F2
Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units.
Footnote F3
The price reported reflects the weighted average sales price. These shares were sold in multiple transactions at prices that were not available from the broker at the time of filing. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
Footnote F4
Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2022 Equity Incentive Plan) through each applicable vesting date, one-third (1/3rd) of the RSUs subject to the award will vest each year following the RSU Grant Date on the same day of the month as the RSU Grant Date (or, if there is no corresponding day in a particular month, then the last day of the month) over three (3) years. "RSU Grant Date" shall mean January 3, 2023.